A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the safety and efficacy of delamanid administered orally as 200 mg total daily dose for 6 months in patients with pulmonary sputum culture-positive, multidrug-resistant tuberculosis.

Trial Profile

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the safety and efficacy of delamanid administered orally as 200 mg total daily dose for 6 months in patients with pulmonary sputum culture-positive, multidrug-resistant tuberculosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Delamanid (Primary)
  • Indications Tuberculosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical; Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 09 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 07 Aug 2016 This trial is completed in Estonia (end date:6 Jun 2016).
    • 04 Aug 2016 This trial is completed in Lithuania (end date:4 Jul 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top